Table 4.
Discontinuation data from the GetGoal study program
| Study | Discontinuation (%)
|
Discontinuation due to AE (%)
|
||
|---|---|---|---|---|
| Lixisenatide | Placebo | Lixisenatide | Placebo | |
| GetGoal-Mono53 | 7.4 | 0.8 | ||
| One-step titration | 9.2 | 2.5 | ||
| Two-step titration | 8.3 | 4.2 | ||
| GetGoal-P59 | 6.5 | 5.0 | ||
| GetGoal-L47 | 7.6 | 4.8 | ||
| GetGoal-S56 | 9.8 | 4.9 | ||
| GetGoal-M51 | ||||
| GetGoal-F155,58 | 5.6 | |||
| One-step titration | 8.7 | |||
| Two-step titration | 11.8 | |||
| GetGoal-L-Asia48 | 13.6 | 8.3 | 9.1 | 3.2 |
| GetGoal-Duo 146 | 13.0 | 5.0 | 8.5 | 3.6 |
| Lixisenatide | Exenatide | Lixisenatide | Exenatide | |
|
| ||||
| GetGoal-X49 | 12.9 | 14.2 | 9.1 | 9.8 |
Notes: One-step titration: 10 μg once daily for 1 week (GetGoal-Mono) or 2 weeks (GetGoal-F1), before reaching the target dose of 20 μg; two-step titration: 10 μg once daily for 1 week followed by 15 μg for 1 week, before reaching the target dose of 20 μg. A lixisenatide target dose of 20 μg once daily was used in all studies. The GetGoal-X study applied an exenatide target dose of 10 μg twice daily.
Abbreviation: AE, adverse event.